| Japanese |
|---|
| Title | 99mTc-SQ30,217心筋イメージングの臨床応用 - 体内動態と撮像時期の検討 - |
|---|
| Subtitle | 原著 |
|---|
| Authors | 大嶽達*, 渡辺俊明*, 小坂昇*, 百瀬敏光*, 西川潤一*, 佐々木康人*, 飯尾正宏**, 栽原伸一郎***, 杉本恒明*** |
|---|
| Authors(kana) | |
|---|
| Organization | *東京大学医学部放射線科, **日本アイソトープ協会, ***東京大学医学部第二内科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 28 |
|---|
| Number | 1 |
|---|
| Page | 71-82 |
|---|
| Year/Month | 1991/1 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」健常人6名を対象とし, 99mTc-SQ30,217の555MBq (15mCi) を静注し, その安全性と体内挙動および撮像時期について検討した. いずれの例にも本剤に起因する副作用や理学所見, 血液・生化学検査, 尿検査などの異常は認められず, 安全性が示唆された. 被曝線量は全身で4.88mGy / 1110MBq (0.488rad), 主要臓器で10mGy以下と許容範囲内であった. 血中消失曲線は二相性を示し, 半減期はα相, β相それぞれ0.02時間, 10.14時間であった. 体内挙動では投与早期の心筋への集積が高いが, 速やかに減少すること, および心肝比, 心肺比とも10分以内は高いが, 15分以後は低下することが特徴と考えられた. 4例の虚血性心疾患患者に経時的SPECT撮像を施行した結果, 投与後早期の撮像でTlとほぼ同等の良好な画像が得られ, 欠損のあらわれ方もほぼ同等であった. 本剤は, 99mTc標識心筋血流製剤として十分使用可能と考えられた. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | 99mTc-SQ30217, Pharmacokinetics, SPECT imaging, Healthy subjects, Myocardial blood-flow. |
|---|
| English |
|---|
| Title | Clinical Application of 99mTc-SQ30,217 Myocardial Imaging - The Study of Pharmacokinetics and Imaging Time - |
|---|
| Subtitle | |
|---|
| Authors | Tohru OHTAKE*, Toshiaki WATANABE*, Noboru KOSAKA*, Toshimitsu MOMOSE*, Jun-ichi NISHIKAWA*, Yasuhito SASAKI*, Masahiro IIO**, Shin-ichiro SAIHARA***, Tsuneaki SUGIMOTO*** |
|---|
| Authors(kana) | |
|---|
| Organization | *Department of Radiology, Faculty of medicine, University of Tokyo, **The Japan Radioisotope Association, ***The Second Department of Internal Medicine, Faculty of Medicine, University of Tokyo |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 28 |
|---|
| Number | 1 |
|---|
| Page | 71-82 |
|---|
| Year/Month | 1991/1 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] 99mTc-SQ30217 555 MBq (15mCi) was intravenously injected to 6 healthy subjects to study its safety, pharmacokinetics and the imaging time. Neither side effect nor abnormalities in physical findings, hematobiochemical tests, urinary test, etc. caused by this agent were observed in any case and its safety was suggested. Radiation dose estimates over the entire body was 4.88 mGy / 1,110 MBq (0.488rad) and that over the major organs was less than 10 mGy and they were within the allowable ranges. 99mTc-SQ30217 showed biphasic disappearance curve in blood with the half-life of α-phase 0.02 hour and that of β-phase 10.14 hours. 99mTc-SQ30217 was considered to show characteristic pharmacokinetics that the myocardial accumulation was high in an early stage of the administration, but it rapidly decreased. Both heart to liver ratio and heart to lung ratio were high within 10 minites, but they decreased after 15 minutes. As a result of SPECT imaging of 4 patients with ischemic cardiac disease, the images obtained with 99mTc-SQ30217 at an early period after the administration was as good as those with 201Tl and the appearance of defects in the images with both agents was similar. 99mTc-SQ30217 was considered to be sufficiently useful as a 99mTc-labelled agent for myocardial blood flow. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | 99mTc-SQ30217, Pharmacokinetics, SPECT imaging, Healthy subjects, Myocardial blood-flow. |
|---|